Viscosupplementation Market is Growing at a Strategic CAGR of 8.96% During Forecast to 2023
Overview:
The
global viscosupplementation market is on a track to score well with a CAGR
of 8.96%, which would help the market in attaining a valuation of USD 5,243.19
million between 2018 and 2023.Market
Research Future (MRFR) discusses the market and considers the time frame as the
forecast period. Viscosupplementationcan be defined as a process that
requires physicians to inject a lubricating fluid-like hyaluronic acid (HA)
injection or hyaluronan injection into a joint as an attempt to treat symptoms various
forms of osteoarthritis like knee, hip, shoulder, ankle, and spine arthritis.
Increasing demand for minimally-invasive surgeries can make sure that the
market gains a better growth rate and fetches good revenues.
Get a Free Sample @ https://www.marketresearchfuture.com/sample_request/7255
Among
other features, initiatives taken by various investors, rising cases of
obesity, diabetes, hypertension, renal failure, gastrointestinal bleeding,
cardiovascular diseases, depression, disability in the geriatric population can
trigger a hike in the growth rate of the Viscosupplementation
Market Share. Women are more prone to this disease. Other things like
lifestyle changes can also impact market growth. Various cases like smoking,
poor nutrition, injuries, and others can influence market growth as well.
Segmentation
The
global Viscosupplementation Market includes segments like
hyaluronic acid type, procedure type, application, and end-user to facilitate an
easy understanding of the market. This method provides a closer look at the
market that can ensure better growth in the coming years.
By
hyaluronic acid type, the global market report for the viscosupplementation
market includes stabilized hyaluronic acid and standard hyaluronic acid. The
stabilized hyaluronic acid segment has the largest market share as its impurity
level is close to zero.
By
procedure type, the market report on theviscosupplementation marketcomprises three-injection
procedure, single-injection procedure, and five-injection procedure. The
three-injection procedure segment has a better opportunity to maintain its
robust growth as it is lower in price when compared with the single-injection
procedures and takes lesstime than the five-injection procedure. Its CAGR could cross a valuation of USD 2602.58
million during the forecast period.
By
application, the market report covering the viscosupplementation market includes
knee arthritis and hip osteoarthritis. The knee arthritis segment has a better
market share than hip osteoarthritis.
By end
user, the market report can be segmented into hospitals & clinics and
ambulatory surgical centers. The hospitals & clinics segment has a larger
share owing to people preferring this setup for their treatment.
Regional Analysis
The
Americas stood at the top in 2017 and has the opportunity to score the highest
CAGR in the coming years. The demand for knee replacement surgeries with
increasing thrust from the minimally-invasive procedures can trigger the growth
of viscosupplementation procedures.
The
Asia-Pacific region has the second-largest market share and can score well-past USD 447.24 million valuations by 2023 with a CAGR
of 10.48% during the forecast period. The region would witness
contributions made by countries like China, India, and others. These are
countries with high expenditure capacity and huge patient pool. In Europe, the
growth would be the most in the UK, where increased awareness regarding the
procedure would trigger better growth.
Competitive Landscape:
Several
players are trying to impact theviscosupplementation market by launching their
strategies that often include mergers, acquisitions, product innovation, and
others. MRFR in its expert analysis of the global market included companies that
have initiated changes in the market with an aim to impact its growth. These
companies are Hoffmann-La Roche, Sanofi, Allergan, Anika Therapeutics
Inc., Bioventus, Regen Lab SA, Zimmer Biomet, Smith & Nephew Plc, Ferring
B.V., FidiaFarmaceutici S.P.A., and others
Access
Full Report Details @ https://www.marketresearchfuture.com/reports/viscosupplementation-market-7255
In
December 2019, Sanofi announced that they are going to implement various
artificial intelligence-driven production models to cut the time consumed
during various productions. This would see the inclusion of collaborative
robots or cobots, which would definitely increase the efficiency of the market.
Comments
Post a Comment